- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07939204
A Single-Arm Phase II Clinical Study of Sacituzumab Tirumotecan Combined With a PD-1 Inhibitor as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma After Failure of or Progression on Immunotherapy
This study is a single-center, single-arm, prospective clinical study enrolling a total of 30 patients with advanced metastatic esophageal squamous cell carcinoma who have failed or progressed after prior first-line immunotherapy or immunotherapy combined with chemotherapy.
After signing the informed consent form, subjects will undergo screening assessment within 28 days prior to the first dose to determine whether they meet the study requirements. Subjects who meet the study inclusion and exclusion criteria will receive sacituzumab tirumotecan and a PD-1 inhibitor.
Patients will receive sacituzumab tirumotecan (4 mg/kg IV d1 Q2W) in combination with a PD-1 inhibitor for 6 cycles, followed by maintenance therapy with a PD-1 inhibitor-based regimen.
until investigator-confirmed radiological disease progression, unacceptable toxicity, the subject's request to discontinue treatment, or other protocol-specified criteria for treatment discontinuation, whichever occurs first; Eligible subjects will undergo regular tumor assessments based on RECIST 1.1. Within 48 weeks (within the first year) after dosing, imaging examinations for tumor assessment will be performed every 6 weeks (±7 days); after 48 weeks, tumor assessment will be performed every 12 weeks (±7 days), until radiological disease progression, initiation of new anti-tumor therapy, withdrawal of informed consent by the subject, loss to follow-up, death, or termination of the study by the sponsor, whichever occurs first. Imaging examinations will be performed as scheduled regardless of dose delay or adjustment. After a patient first achieves complete response (CR) or partial response (PR), the observed response must be confirmed at least 4 weeks (28 days) later.
For subjects who discontinue treatment for reasons other than radiological disease progression, death or loss to follow-up, imaging examinations should be repeated at the EOT visit if more than 4 weeks have elapsed since the previous imaging examination; subsequent imaging examinations should be performed as scheduled as far as possible until radiological disease progression, initiation of new anti-tumor therapy, withdrawal of informed consent by the subject, loss to follow-up, death, or termination of the study by the sponsor, whichever occurs first.
After the end of treatment, regardless of whether a new anti-tumor therapy is initiated, safety follow-up must be completed for the subject, and survival follow-up visits will be continued by telephone every 3 months (±14 days) after the last dose of study treatment to obtain survival information and information on new anti-tumor therapy, until the subject decides to withdraw from the study, loss to follow-up, death, or the end of the study, whichever occurs first.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Rui Liu
- Telefonnummer: 022 23340123
- E-post: liurui9003@163.com
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histopathologically confirmed unresectable advanced metastatic esophageal squamous cell carcinoma;
- Age 18-75 years, male or female;
- At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (iRECIST 1.1); measurable lesions should not have received prior local therapy such as radiotherapy;
- Failure (disease progression or unacceptable toxicity) of prior first-line immunotherapy or immunotherapy combined with chemotherapy; patients who relapse within 6 months after the end of adjuvant/neoadjuvant therapy, if the treatment regimen was immunotherapy or immunotherapy combined with chemotherapy, will be regarded as having failed first-line treatment and may be enrolled;
- Expected survival of ≥12 weeks;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before dosing;
- Radiologically confirmed disease progression during or after the most recent treatment for advanced or metastatic disease;
- Adequate organ and bone marrow function (no blood transfusion, recombinant human thrombopoietin or colony-stimulating factor within 2 weeks prior to the first dose)
- Female subjects of childbearing potential and male subjects whose partners are of childbearing potential must agree to use effective medical contraception from the signing of the informed consent form until 6 months after the last dose; 10) Subjects voluntarily participate in this study, sign the informed consent form, and are able to comply with the visits and related procedures specified in the protocol.
Exclusion Criteria:
- Subjects with known meningeal metastasis, brainstem metastasis, spinal metastasis and/or compression, or active or untreated central nervous system (CNS) metastasis. Subjects with brain metastasis who have received prior local therapy may be enrolled if they are clinically stable for at least 4 weeks before dosing and do not require glucocorticoids or anticonvulsants for at least 14 days;
- Patients who experienced disease progression within 3 months during prior first-line treatment;
- Prior receipt of TROP2-targeted therapy; prior receipt of any topoisomerase I inhibitor drug or chemotherapy;
- Presence of persistent or active infection;
- Participation in other anti-tumor drug clinical trials within 4 weeks before screening;
- Presence of adverse events of CTCAE > Grade 1 before the first dose (excluding alopecia and endocrine toxicity);
- Presence of other uncured malignancies within 5 years (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
- Positive human immunodeficiency virus (HIV) test or a history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection;
- Known hypersensitivity to the study drug or any of its components;
- History of (non-infectious) interstitial lung disease (ILD) or non-infectious pneumonitis requiring steroid treatment, current ILD or non-infectious pneumonitis, or suspected ILD or non-infectious pneumonitis that cannot be excluded by imaging examination at screening;
- Poorly controlled diabetes mellitus (fasting blood glucose ≥ 10 mmol/L on two consecutive measurements);
- Presence of clinically symptomatic pleural effusion, pericardial effusion or ascites requiring repeated drainage (> once per week);
- Documented severe dry eye syndrome, severe meibomian gland disease and/or blepharitis, or a history of corneal disease that prevents or delays corneal healing; Any condition that, in the investigator's judgment, interferes with the evaluation of the study drug, the safety of the subject or the interpretation of study results, or any other condition considered by the investigator to make the subject unsuitable for participation in this study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Sacituzumab tirumotecan combined with PD-1 inhibitor
Patients will receive sacituzumab tirumotecan (4 mg/kg IV d1 Q2W) in combination with a PD-1 inhibitor for 6 cycles, followed by maintenance therapy with a PD-1 inhibitor-based regimen. |
Patients will receive sacituzumab tirumotecan (4 mg/kg IV d1 Q2W) in combination with a PD-1 inhibitor for 6 cycles, followed by maintenance therapy with a PD-1 inhibitor-based regimen.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
progression-free survival (PFS)
Tidsram: 2years
|
To evaluate progression-free survival (PFS) with sacituzumab tirumotecan combined with a PD-1 inhibitor: the time from enrollment to radiologically confirmed disease progression (PD) (per iRECIST 1.1) or death from any cause without documented progression; |
2years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
objective response rate (ORR)
Tidsram: 1year
|
To evaluate the objective response rate (ORR) of sacituzumab tirumotecan combined with a PD-1 inhibitor: per iRECIST 1.1, the proportion of patients whose best overall response from enrollment to disease progression is CR or PR among all evaluable patients; |
1year
|
|
overall survival (OS)
Tidsram: 3years
|
To evaluate overall survival (OS) with sacituzumab tirumotecan combined with a PD-1 inhibitor: the time from enrollment to death from any cause; |
3years
|
|
duration of response (DOR)
Tidsram: 1year
|
To evaluate the duration of response (DOR) with sacituzumab tirumotecan combined with a PD-1 inhibitor: the time from the first assessment meeting CR or PR criteria to the observation of PD or death, whichever occurs first; calculated only for patients whose best overall response is CR or PR |
1year
|
|
adverse events (AEs)
Tidsram: 2years
|
During this study and the follow-up period, the severity of adverse events will be graded and assessed according to NCI CTCAE (version 5.0). Safety evaluation indicators include: The incidence, severity and relationship to the study drug of all adverse events (AEs), treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs); The number and proportion of subjects with dose reduction and treatment discontinuation due to the above adverse events; Changes in vital signs, physical examination findings and laboratory results before, during and after study treatment. |
2years
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter plats
- Neoplasmer
- Neoplasmer efter histologisk typ
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Gastrointestinala sjukdomar
- Neoplasmer i huvud och hals
- Neoplasmer, körtel och epitel
- Esofagussjukdomar
- Carcinom
- Neoplasmer, skivepitelceller
- Karcinom, skivepitel
- Esofagusneoplasmer
- Esofagus skivepitelcancer
- Antineoplastiska medel, immunologiska
- Antineoplastiska medel
- Molekylära mekanismer för farmakologisk verkan
- Farmakologiska åtgärder
- Kemiska åtgärder och användningar
- Terapeutisk användning
- Immune Checkpoint-hämmare
Andra studie-ID-nummer
- E20261246
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .